Education
About Us
Working with TipRanks
Follow Us
Bluebird bio Inc (BLUE)
:BLUE
BLUE Stock Chart & Stats
Day’s RangeN/A
52-Week Range― - ―
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Bluebird Bio News
BLUE FAQ
What was Bluebird bio Inc’s price range in the past 12 months?
Currently, no data Available
What is Bluebird bio Inc’s market cap?
Currently, no data Available
When is Bluebird bio Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Bluebird bio Inc’s earnings last quarter?
Currently, no data Available
Is Bluebird bio Inc overvalued?
According to Wall Street analysts Bluebird bio Inc’s price is currently Undervalued.
Does Bluebird bio Inc pay dividends?
Bluebird bio Inc does not currently pay dividends.
What is Bluebird bio Inc’s EPS estimate?
Bluebird bio Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bluebird bio Inc have?
Currently, no data Available
What happened to Bluebird bio Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Bluebird bio Inc?
Currently, no hedge funds are holding shares in BLUE
Company Description
Bluebird bio Inc
Bluebird Bio, Inc. (BLUE) is a biotechnology company specializing in the development of gene therapies for severe genetic diseases and cancer. The company focuses on developing therapies that address the underlying genetic causes of these conditions, primarily through the use of lentiviral-based gene therapies. Bluebird Bio's core products are designed to treat conditions such as beta-thalassemia, sickle cell disease, and cerebral adrenoleukodystrophy.
Ownership Overview
―
Insiders
1.13%
Mutual Funds
― Other Institutional Investors
98.87% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---